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Summary Although cancer of the cervix is traditionally considered not to be responsive to steroid hormones, an in vitro study has reported
that the addition of oestrogen increased cellular proliferation in a cervix cancer cell line that was inhibited by progesterone. We investigated
whether the reported in vitro effects of oestrogen and progesterone on cellular proliferation can be replicated in locally advanced cervical
cancer in vivo and whether these effects, if any, are related to oestrogen and progesterone receptor (ER and PgR) content of the tumour. One
hundred post-menopausal patients with locally advanced cervical cancer were systematically allocated by rotation to the four treatment
groups: (1) control group receiving no treatment; (2) ethinyl oestradiol 50 gg; (3) norethisterone 5 mg; (4) a combination of ethinyl oestradiol
and norethisterone. Hormone treatment (five doses) was given orally every 12 h. Tissue biopsies were taken before and 12 h after the last
hormone treatment. S-phase fraction (SpF) was measured by flow cytometry, and ER and PgR were measured by enzyme immunoassay.
Results were analysed using two-factor analysis of variance, the factors being oestrogen - absent or present - and progesterone - absent or
present. The main effects of oestrogen were increases in SpF, ER and PgR, which were statistically significant (P= 0.0056, 0.0009 and 0.01
respectively), indicating that there is much greater change in these three parameters in the presence of oestrogen (mean changes 7.808 %,
6.258 fmol mg-' and 12.716 fmol mg-' for SpF, ER and PgR respectively) than in its absence (mean change -1.986 %, -3.041 fmol mg-' and
1.736 fmol mg-' respectively). The progestogen main effect and the oestrogen - progestogen interaction were not significant. The rise in SpF,
ER and PgR in the presence of oestrogen had a correlation coefficient with the initial ER values of -0.0565, -0.2863 and -0.1230
respectively, none being statistically significant, suggesting that the oestrogen actions were not strictly related to baseline ER concentrations.
The combined median baseline ER and PgR values of the four groups were 1.48 fmol mg-' and 0.80 fmol mg-' respectively. Our results show
that oestrogen is capable of increasing SpF in locally advanced cervical cancer in vivo and may help to revive interest in the use of oestrogen
as a radiosensitizing agent in the treatment of this disease.
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Carcinoma ofthe cervix is the commonest cancer in women in the
developing world where most patients present at advanced stages
when treatment with radiotherapy is not very effective (Hoskins et
al, 1993). At least two studies have used adjuvant oestrogen treat-
ment in an attempt to increase sensitivity of squamous cell carci-
noma ofthe cervix to radiation therapy (Runge, 1959; Sugimori et
al, 1976). One of these studies reported a significantly better
survival in stage III patients in whom oestrogen was administered
before and during radiation treatment than in the control group
(Sugimori et al, 1976). Cancer of the cervix is conventionally not
considered to be steroid hormone-responsive tissue. However, one
report has claimed that a human cervical carcinoma cell line HOG-
1 could be made to proliferate by the addition ofoestradiol, which
was inhibited by progesterone (White et al, 1992). In breast cancer,
several studies of oestrogen priming have been conducted in an
attempt to recruit cells in the proliferative phase of the cell cycle
to enhance sensitivity of tumours to chemotherapy (Conte et al,
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1985; Fabian et al, 1994). We conducted the present study to
investigate whether short-term treatment with oral ethinyl oestra-
diol could increase the fraction of cells in the S-phase (SpF) in
locally advanced cervical cancer in vivo. As progesterone has been
shown to inhibit the effect of oestrogen on cell proliferation in a
cervical carcinoma cell line (White et al, 1992), we also studied
the effect on SpF of oral noresthisterone, a progestogen, alone or
in combination with oestrogen. The effects of these hormones on
oestrogen and progesterone receptors (ER and PgR) were also
investigated.
MATERIALS AND METHODS
Between January 1993 and August 1994, 100 post-menopausal
women with locally advanced carcinoma of the cervix (FIGO
stage IIB or above) were recruited into the study. Of these, 49%
were FIGO stage IIB, 47% were stage IIIB and 4% were stage
IVA. The ages of these patients varied between 45 and 72 years,
with a mean of 55.34 ± 7.55 (s.d.) years. Histopathological biopsy
reports revealed that 93% were squamous cell carcinomas, 6%
were adenosquamous carcinomas and 1% adenocarcinoma. Nine
per cent of the carcinomas were of histological grade I, 62% of
grade II and 29% ofgrade III.
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Figure 1 Scatter plots showing changes in SpF, ER and PgR in response to hormones. (A) Control group; (B) oestrogen-treated group; (C) progestogen-
treated group; (D) combination group. For dose see text
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Table 1 Table of means
No E (n) E (n) No E + E (n)
SpF difference (%)
No P 0.231 (25) 8.871 (24) 4.55a (49)
P -4.204 (23) 6.745 (20) 1.270a (43)
No P + P -1.986b (48) 7.808b (44)
ER difference (fmol mg-')
No P -3.800 7.677 1.938a
P -2.281 4.839 1.279a
No P + P -3.041b 6.258b
PgR difference (fmol mg-')
No P -0.346 17.277 8.465a
P 3.818 8.154 5.986a
No P + P 1.736b 12.716b
aComparison of effects of progestogen, ignoring oestrogen. bComparison of
effects of oestrogen, ignoring progestogen. E, Oestrogen; P, progestogen.
Table 2 Summary analyses of variance
Sum of squares d.f. Mean square e P-value
SpF difference
E 2190.83 1 2190.83 8.07 0.0056
P 245.84 1 245.84 0.91 0.3439
EP 30.47 1 30.47 0.11 0.7384
Error 23894.34 88 271.53
ER difference
E 1974.81 1 1974.81 11.93 0.0009
P 9.93 1 9.93 0.06 0.81
EP 108.40 1 108.40 0.66 0.42
Error 14562.62 88 165.48
PgR difference
E 2753.19 1 2753.19 6.86 0.01
P 140.37 1 140.37 0.35 0.56
EP 1008.10 1 1008.10 2.51 0.12
Error 35315.76 88 401.32
E, Oestrogen; P, progestogen; EP, interaction of E and P.
After general examination for fitness, all patients in the study
were admitted to hospital to ensure compliance to the treatment
regimens. After exposing the cervical growth with the help of a
Cusco speculum, a punch biopsy was taken from the periphery of
the tumouravoiding the central necrotic area. A part ofthe primary
biopsy (Bx 1) was sent for histopathology and the remainder kept
frozen at -80°C in 12% dimethyl sulphoxide in Dulbecco's modi-
fied Eagle medium for flow-cytometric (FCM) analysis. Another
part of the specimen was wrapped in aluminium foil and stored at
-80°C for ER and PgR assays.
The patients were not randomized but systematically allocated
to the following four treatment arms strictly by rotation, i.e. (1) no
treatment, (2) ethinyl oestradiol 50 jg orally every 12 h x five
doses, (3) norethisterone 5 mg orally every 12 h x five doses, (4)
combination of ethinyl oestradiol and norethisterone orally every
12 h x five doses. The above dose levels were chosen as these
are within the therapeutic range for these hormones when used
for conditions such as dysfunctional uterine bleeding (Wentz,
1988). Twelve hours after the last hormone dose, a second biopsy
(Bx 2) was taken and stored in the same fashion for flow cytom-
etry analysis and ER and PgR assays. Radiation therapy was
commenced immediately after the second biopsy.
This study was conducted after obtaining approval from the
institutional review body, and a written informed consent was
obtained from all participating women.
Flow cytometry was performed using the Epics Profile machine
(Coulter, Hialea, FL USA). A single-cell suspension was prepared
from each frozen tumour sample, fixed in 70% chilled ethanol and
stained with propidium iodide (50 jg ml-'). Approximately 1-2 x
106 cells were used for each analysis. Normal human peripheral
blood lymphocytes separated on Ficoll were used as a diploid
reference standard in each assay batch. The data were stored in a
histogram mode on hard disk for later retrieval. Cell cycle analysis
was performed using the multicycle software from Phoenix Flow
Systems, San Diego, CA, USA. For every case both ploidy status
and SpF were measured. Eight biopsy samples (either Bx 1 or Bx
2) generated unsatisfactory histograms that could not be inter-
preted. These eight cases were excluded from the study.
ER and PgR assay was performed by an enzyme immunoassay
(EIA) technique using the Abbot kit (Nolan et al, 1987). The
method involves the use oftwo distinct antibodies to each receptor
in a 'sandwich' technique. Bx 1 and Bx 2 samples from each
patient were always analysed in the same assay batch.
Ofthe 100 patients, 92 samples were evaluable for SpF, ER and
PgR for both Bx 1 and Bx 2. Consequently, there were 25 patients
in the control group, 24 in the oestrogen-treated group, 23 in the
progestogen-treated group and 20 patients in the combined treat-
ment group.
RESULTS
Figure 1 depicts scatter plots of SpF, ER and PgR values of Bx 1
and Bx 2 in the four treatment groups. The changes in SpF, ER and
PgR in the four groups were analysed statistically using two-factor
analyses of variance, the factors being oestrogen (E) - absent or
present - and progestogen (P) - absent or present. These give tests
ofthe main effects ofE and P and a test ofthe interaction ofE and
P (EP). The calculations were carried out on the raw untrans-
formed data and were checked using logarithmically transformed
data because ofthe presence ofpositive skew in the raw data. The
results ofthe logarithmically transformed data analyses will not be
shown separately, as the conclusion on these analyses were iden-
tical to those from the raw data analyses.
The main effects of oestrogen and progestogen on SpF, ER and
PgR are shown in Table 1. Table 2 summarizes the analyses of
variance ofdifferences in SpF, ER and PgR.
S-phase fraction
A comparison of the means of no E vs E groups gives the main
effect of oestrogen, that is, the mean changes in SpF without and
with oestrogen ignoring progestogen (Table 1). The mean per cent
SpF difference without oestrogen (combining the no progestogen
and progestogen groups) is 1.986, while with oestrogen the mean
change is 7.808. Similarly, the main effect ofprogestogen on SpF is
seen from the comparison of mean per cent changes without and
with progestogen, ignoring oestrogen. The overall mean SpFdiffer-
ence without progestogen is 4.55 and with progestogen is 1.270.
Table 2 gives the summary analysis of variance of the data. It
shows that the main effect ofE on SpF is statistically significant (P
= 0.0056), indicating that there is a much greater change in SpF in
the presence of oestrogen (mean change 7.808%) than in its
absence (mean change -1.986%, Table 1). The P main effect and
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the EP interaction are both non-significant (P = 0.3439 and 0.7384
respectively); the former being consistent with there being no
progestogen effect and the latter with there being no modification
by progestogen of the oestrogen effect.
The rise in SpF in the presence of oestrogen has a correlation
coefficient of -0.057 with the initial ER value and 0.227 with the
initial PgR value, neither being statistically significant. Similarly,
correlation coefficient of the SpF rise in the presence of oestrogen
with post-treatment (Bx 2) values of ER and PgR were also statis-
tically non-significant (-0.2265 and 0.0599 respectively). The
combined median baseline ER and PgR values of the four groups
were 1.48 fmol mg-' and 0.80 fmol mg-' respectively. Only
17.40% ofER and 4.35% ofPgR were above the conventional cut-
off level of 10 fmol mg-' which is used in breast cancer to distin-
guish receptor-positive and receptor-negative tumours.
Oestrogen receptor
The main effect ofE on ER is statistically significant (P = 0.0009,
Table 2), indicating that there is a much greater change in ER in
the presence of oestrogen (mean change 6.258 fmol mg') than in
its absence (mean change 3.041 fmol mg', Table 1). The P main
effect on ER and the EP interaction are both non-significant (P =
0.81 and 0.42 respectively); the former being consistent with there
being no progestogen effect and the latter with there being no
modification by progestogen ofthe oestrogen effect.
The rise in ER in the presence of oestrogen has a correlation
coefficient of -0.2863 with initial ER value and -0.1490 with
initial PgR value, neither being statistically significant.
Progesterone receptor
The main effect of E on PgR is statistically significant (P = 0.01,
Table 2), indicating that there is a much greater change in PgR in
the presence of oestrogen (mean change 12.716 fmol mg') than in
its absence (mean change 1.736 fmol mg', Table 1). The P main
effect on PgR and the EP interaction are both non-significant (P =
0.56 and 0.12 respectively); the former being consistent with there
being no progestogen effect and the latter with there being no
modification by progestogen ofthe oestrogen effect.
The rise in PgR in the presence of oestrogen has a correlation
coefficient of-0.1230 with initial ER and -0.0254 with initial PgR
value, neither being statistically significant.
DISCUSSION
Our study demonstrates that short-term treatment with ethinyl
oestradiol given orally in 'physiological' doses causes a significant
rise in SpF, ER and PgR concentrations in post-menopausal women
with locally advanced cervical carcinoma. Norethisterone, a
progestogen, had no effect on the above biological parameters, nor
did it have any interaction with the oestrogen effect when given in
combination with ethinyl oestradiol. To our knowledge, a prolifera-
tive effect of oestradiol on cervical cancer in vivo has, so far, not
been demonstrated. The lack of a progestogen effect in our study
might have been as a result of the dose level that was used. It
remains to be seen whether progestogen in higher doses can
suppress SpF or can counteract the proliferative effect ofoestrogen.
We observed that oestrogen administration caused a significant
rise in PgR levels in cervical cancer. Although it is well established
that oestrogen induces PgR in human breast cancer (Horwitz and
McGuire, 1978), such an effect had so far not been demonstrated in
cervical cancer. We also observed that oestrogen administration
caused the induction of its own receptor. This phenomenon has not
been widely recognized in humans, although oestrogen-stimulated
induction of its own receptor has been reported in several animal
models (McCormach and Glasser, 1980; Sutherland et al, 1980;
Lessey et al, 1981). Piva et al (1988) have demonstrated an increase
in ER mRNA in human breast cancer cell lines cultured with
oestradiol. ER was shown to increase in normal cervicovaginal
epithelium in four post-menopausal women after treatment with
vaginal oestrogen pesseries (Punnonen and Lukola, 1982). The
highly significant increase in ER in patients receiving oestrogen
was, however, unaffected by the simultaneous administration of
progestogen in the dose levels used.
Although cancer of the cervix is considered not to be responsive
to steroid hormones, the normal cervix is known to respond
actively to sex steroids (Soutter and Leake, 1987). The presence of
oestrogen receptor was reported in all the samples of normal
cervical tissue examined in premenopausal woman (Soutter et al,
1981, 1983). Several authors have measured ER and PgR levels in
cervical cancer (see Soutter and Leake, 1987 for review).
However, the proportion showing their presence have been vari-
able. For example, Vargas et al (1993) and Hahnel et al (1979)
reported low or undetectable levels of ER and PgR in cervical
cancer using immunohistochemical and ligand-binding assays
respectively. Other workers using the latter technique have
reported somewhat higher levels (Ford et al, 1983; Gao et al, 1983;
Hunter et al, 1987). The differences between studies may be the
result of differences in method for tissue collection, differences in
storage conditions, differences in assay techniques and perhaps
differences in patient populations. Soutter and Leake (1987) have
reported better preservation of steroid receptors when tissues are
stored in a hyperosmolar glycerol buffer rather than in liquid
nitrogen. In their study, using these storage conditions, oestrogen
receptors were found in 45.2% of 73 squamous tumours. In our
study, in which an EIA technique was used, ER and PgR were
found in 90.2% and 81.5% of tumours; but the values were gener-
ally low with median figures of 1.48 fmol mg-' and 0.80 fmol mg-'
respectively. We scored all tissues in which ER and PgR values
could be recorded as evidence for presence ofreceptors. Perhaps a
better alternative would have been to include squamous cell carci-
nomas from non-reproductive tissues as negative controls to deter-
mine a cut-off value. It has been generally observed that ER and
PgR levels are higher in adenocarcinomas than in squamous cell
carcinomas of the cervix (Hahnel et al, 1979; Ford et al, 1983).
The relatively low receptor values observed in our study may be
related to the fact that 93% of the tumours included in our study
were of squamous cell origin. We did not find any relationship
between steroid receptor levels and stage ofdisease.
Although the levels of ER and PgR observed in cervix cancer
are relatively low compared with those detected in breast cancer,
these levels were nevertheless apparently sufficient to bring about
the biological changes observed. Our finding that oestrogen
administration caused cellular proliferation and the induction of
PgR clearly indicates that the action of oestradiol was mediated
via the ER pathway. It is possible that, in spite oflow levels ofER,
there may be very important differences in ER contents among
cells in the tissue biopsy, and that those cells that express ER are
the cells that respond to increases in SpF following oestrogen
treatment. This issue would need to be resolved by simultaneous
analysis of ER and cells that are proliferating, e.g. by double
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immunohistochemical analysis. Our failure to detect a correlation
between initial ER levels and biological action may either be
related to the above phenomen or to the generally low levels
and narrow range of ER recorded. The mediation of biological
effects ofoestrogen in the presence of low receptor concentrations
has been observed in certain parts ofthe brain (Bettini et al, 1992)
and several other organs (see Ciocca and Vargas-Roig, 1995 for
review). It is now recognised that most, if not all, mammalian
tissues contain small amounts ofER (Jensen et al, 1982), and it has
been suggested that the very presence of high levels of ER should
not be the sole definition ofan oestrogen-target tissue. A target cell
may not contain ER but may still be called a target if it is affected
specifically and directly by oestrogen stimulation (Ciocca and
Vargas Roig, 1995).
Two studies have investigated the use of adjuvant oestrogen
treatment in an attempt to increase sensitivity of squamous cell
carcinoma of the cervix to radiation therapy (Runge, 1959;
Sugimori et al, 1976). In the first study comprising of 126 stage II
and III patients, the simultaneous administration of oestrogens
to radiotherapy improved the 5-year survival from 25.0% to
37.9% (Runge, 1959). This difference was, however, not statisti-
cally significant. The study by Sugimori et al (1976) showed an
improvement in 5-year survival that was significant in the study as
a whole (42.6-60.5%) and for the sub-group of stage III patients
(34.4-55.2%). However, in this study, the method of randomiza-
tion used would be considered unacceptable by modern standards
and hence the evidence cannot be regarded as conclusive.
Both these studies were undertaken in the belief that oestrogen
would improve blood supply to the tumour resulting in better
oxygenation and consequently making the tumour more radiosen-
sitive. An alternative hypothesis for oestrogen radiosensitization
proposes that the hormone, which is concentrated in the nucleus of
tumour cells, might release cytotoxic free radicals in the vicinity of
the genome under the influence of radiotherapy (Soutter and
Leake, 1987). However, cervical cancer cells in GI/M phase ofthe
cell cycles are also believed to be more radiosensitive than those in
G(/G, phase (Yu et al, 1991). Similarly, it was observed in a series
of 326 cases of laryngeal cancer that those with a low SpF had a
higher frequency of local recurrence following radiotherapy than
those with high SpF (Tennvall, et al, 1993). Our study raises the
possibility that simultaneous treatment with oestrogen during
radiotherapy for cervical cancer might enhance radiosensitivity by
recruitment of a greater proportion of cells into the G,/M phase of
the cell cycle under influence of the steroid hormone. We propose
to undertake a randomized trial to test this hypothesis.
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